Anpac Bio is launching a new facility in Pennsylvania.
Dr. Reddington has over 20 years of diverse experience encompassing marketing and sales, management, business development, discovery research, pre-clinical testing and clinical trials with private and public biotechnology companies.
John J. Reddington, DVM, PhD
Technical Board Consultant

• Former Chief operating officer for Cambridge Biomedical Inc., a privately held laboratory CRO

• Previously he served as president and CEO of Sirtex Medical, Inc., the U.S. division of an Australian publicly traded company, Sirtex Medical Group Ltd.

• Prior to joining Sirtex, John was COO and SVP of R&D for the publicly traded company Valentis Inc., where he played a key role in transitioning Valentis’ clinical focus from gene therapy to poloxamer-based therapeutics to treat cardiovascular disease.